Literature DB >> 1371038

Mechanism of action of foscarnet against viral polymerases.

C S Crumpacker1.   

Abstract

Foscarnet is a pyrophosphate analogue with activity against herpesviruses, human immunodeficiency virus (HIV), and other RNA and DNA viruses. Foscarnet and its analogues achieve their antiviral effects via inhibition of viral polymerases, with such inhibition not being dependent on activation or phosphorylation of the compounds by viral or cellular proteins. Current evidence indicates that foscarnet interferes with exchange of pyrophosphate from deoxynucleoside triphosphate during viral replication by binding to a site on the herpesvirus DNA polymerase or HIV reverse transcriptase. Reviewed herein are basic findings regarding the mechanism of action and antiviral activity of foscarnet and the related compound phosphonoacetic acid (PAA), as well as findings regarding potential mechanisms of viral resistance and interactions with other antiviral agents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371038     DOI: 10.1016/0002-9343(92)90329-a

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  33 in total

1.  Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.

Authors:  J L Hammond; D L Koontz; H Z Bazmi; J R Beadle; S E Hostetler; G D Kini; K A Aldern; D D Richman; K Y Hostetler; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Characterization of the DNA- and dNTP-binding activities of the human cytomegalovirus DNA polymerase catalytic subunit UL54.

Authors:  Frédéric Picard-Jean; Isabelle Bougie; Martin Bisaillon
Journal:  Biochem J       Date:  2007-11-01       Impact factor: 3.857

3.  Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.

Authors:  Egor P Tchesnokov; Christian Gilbert; Guy Boivin; Matthias Götte
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 4.  The search for new therapies for human cytomegalovirus infections.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Virus Res       Date:  2010-11-21       Impact factor: 3.303

5.  Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription.

Authors:  C W Hooker; W B Lott; D Harrich
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections.

Authors:  Kevin M Tyo; Amanda B Lasnik; Longyun Zhang; Mohamed Mahmoud; Alfred B Jenson; Joshua L Fuqua; Kenneth E Palmer; Jill M Steinbach-Rankins
Journal:  J Control Release       Date:  2020-02-05       Impact factor: 9.776

7.  Recombinant human hepatitis B virus reverse transcriptase is active in the absence of the nucleocapsid or the viral replication origin, DR1.

Authors:  M Seifer; D N Standring
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

8.  Fulminant hepatic failure secondary to acyclovir-resistant herpes simplex virus.

Authors:  Lokesh Shahani
Journal:  BMJ Case Rep       Date:  2016-10-17

Review 9.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

10.  Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor.

Authors:  Stephen W Mason; Carol Lawetz; Yvon Gaudette; Florence Dô; Erika Scouten; Lisette Lagacé; Bruno Simoneau; Michel Liuzzi
Journal:  Nucleic Acids Res       Date:  2004-09-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.